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Large scale human genetic studies have shown that loss of function (LoF) mutations in MYT1L are implicated in
neurodevelopmental disorders (NDDs). Here, we provide an overview of the growing number of published MYT1L patient cases,
and summarize prior studies in cells, zebraﬁsh, and mice, both to understand MYT1L’s molecular and cellular role during brain
development and consider how its dysfunction can lead to NDDs. We integrate the conclusions from these studies and highlight
conﬂicting ﬁndings to reassess the current model of the role of MYT1L as a transcriptional activator and/or repressor based on the
biological context. Finally, we highlight additional functional studies that are needed to understand the molecular mechanisms
underlying pathophysiology and propose key questions to guide future preclinical studies.
Translational Psychiatry (2022)12:292 ; https://doi.org/10.1038/s41398-022-02058-x

INTRODUCTION
Human genetic studies recently associated the gene Myelin
Transcription Factor 1 Like (MYT1L) with neurodevelopmental
disorders (NDDs) [1–9]. Speciﬁcally, MYT1L loss of function (LoF) is
associated with intellectual disability (ID) and autism spectrum
disorder (ASD), while MYT1L duplication has been observed in
patients with schizophrenia (SCZ) [10]. Yet, the mechanism by which
MYT1L variants contribute to disease pathology is still unknown.
MYT1L, along with Myelin Transcription Factor 1 (MYT1) and
Suppression of Tumorigenicity 18 (ST18/MYT3), is part of the
three-gene MYT/neural zinc ﬁnger (NZF) transcription factor (TF)
family. These TFs are characterized by DNA binding C2HC-type
zinc ﬁngers, and a MYT1 domain, which is hypothesized to
function as a transcriptional repressor [11, 12]. While all three TFs
are found to be expressed in the developing brain, MYT1L has
speciﬁcally been shown to enhance neuronal differentiation
[11,13]. Seminal studies have shown that overexpression of ASCL1
and BRN2 reprograms ﬁbroblasts into functional neurons in vitro
and the addition of MYT1L signiﬁcantly increases conversion
efﬁciency [14]. However, the exact role of MYT1L during this
transdifferentiation process remains poorly understood. As a
member of MYT/NZF protein family, it is thought that MYT1L
represses its target genes’ expression, reminiscent of the known
repressive functions of MYT1. Indeed, in vitro neuronal transdifferentiation studies demonstrated that MYT1L represses nonneuronal gene expression, while promoting neuronal differentiation [11]. On the other hand, both in vitro and in vivo studies
indicate MYT1L can activate gene expression with a comparable
magnitude to reported repression, suggesting that it can also
function as an activator [15, 16]. Further studies are needed to
resolve its true molecular function in biologically relevant
contexts.

In this review, we ﬁrst discuss the association between MYT1L
variants and human disease phenotypes. Then, we integrate
results from in vitro studies to summarize the known cellular and
molecular functions of MYT1L. Finally, we identify key outstanding
questions and propose future directions for MYT1L studies with a
focus on cutting-edge techniques that could elucidate MYT1L’s
function in even greater depth. We hope this review will serve as a
primer on the current state of research into this emerging
NDD-associated gene and highlight opportunities for future
investigation.
THE ASSOCIATION OF MYT1L MUTATION AND HUMAN
DISEASE
Human genetic studies have identiﬁed genetic mutations in
transcription factors and chromatin remodelers (MECP2, CHD8,
SETD5, etc.) as causes for various forms of neuropsychiatric
disorders, ID, ASD, and SCZ [2, 3, 7, 17–19]. One of these newly
associated factors is MYT1L.
With the increased integration of genome sequencing into the
clinic over the last 10 years, MYT1L mutations, mostly de novo,
have consistently been found in patients with early onset
neurological disorders. Currently, there are over 100 described
patients with MYT1L mutations, with 80% of them harboring
potential MYT1L LoF mutations and others harboring MYT1L partial
duplications [5, 8, 10, 20]. MYT1L LoF mutations include deletions,
frameshift, and single nucleotide variations (SNVs), which are
predicted to cause decreases in mRNA production or aberrant
protein functions. Notably, missense mutations from clinical but
not general-population studies cluster in the central zinc ﬁnger
domains and the MYT1 domain [21, 22] (Fig. 1A), the most
conﬁdent structures predicted by AlphaFold (Fig. 1B,
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Fig. 1 Schematic of human MYT1L domains and predicted protein structure by AlphaFold. A Distribution of missense mutations described
in clinical studies (top, red) compared to a general population sample (gnomAD, bottom, with gray bars displaying all missense mutations and
black bars displaying ‘possible damaging mutations’ as predicted by PolyPhen2). ‘Possible damaging mutations’ in the general population are
largely excluded from the regions mutated in clinical samples. B AlphaFold’s calculated conﬁdence measure (pLDDT score) per-residue of the
model’s prediction based on the IDDT-Cα metric. C 3D AlphaFold structure (AF-Q9UL68-F1) prediction of MYT1L protein showing the
N-terminal domain (magenta), MYT1 domain (orange), coiled domain (yellow), and six zinc ﬁnger domains (blue) coming in proximity with
each other to form a putative DNA-binding pocket. Unannotated regions are shown in green. (https://alphafold.ebi.ac.uk/entry/Q9UL68).
D Loss of function mutations from patient reports are found throughout the protein. Those not within the annotated zinc ﬁnger domains
(blue) are shown in red. E Isolated and magniﬁed view of the zinc ﬁnger domains (blue) shows patient mutations (cyan) cluster in the zinc
ﬁngers.

Supplemental Videos 1, 2), indicating these domains might be
crucial for the protein’s functions [23, 24]. Among patients with
MYT1L LoF mutations, ID, ASD, and developmental delay are the
most common symptoms. Other phenotypes include seizures,
syndromic obesity, microcephaly, macrocephaly, and muscular
hypotonia. This constellation of symptoms has now been
recognized as MYT1L Syndrome or 2p25.3 Deletion Syndrome
[5, 8, 10, 20]. In addition, most patients with MYT1L partial
duplications were reported to either have ID, ASD, or both. It
seems these developmental impacts of MYT1L haploinsufﬁciency
indicate a well-conserved role for the protein: across two labs, with
independently generated lines, MYT1L haploinsufﬁcient mice
were also shown to have obesity, hyperactivity, and social deﬁcits
[15, 25].
Finally, regarding MYT1L duplications in humans, although 33%
of MYT1L duplication patients presented with SCZ exclusively, all

but one of those duplications contain neighboring gene PXDN,
indicating MYT1L may not be the only contributing factor in the
region for SCZ risk [10]. The association of both LoF and putative
duplications with disease indicates that neurobiology is very
sensitive to the levels of MYT1L activity and identifying the loci
that are inﬂuenced by altered MYT1L levels might aid in
understanding the downstream pathophysiology. Therefore, in
the following sections, we summarize previous studies on MYT1L
to provide mechanistic insights into its cellular and molecular
functions under different contexts.
CELLULAR FUNCTIONS OF MYT1L
MYT1L functions to promote neuronal maturation
Neuronal identity is determined by the effects of a combination of
basic helix-loop-helix (bHLH) TFs (i.e., ASCL1, NEUROD1, and
Translational Psychiatry (2022)12:292

J. Chen et al.

3
Myt Family mRNA
Expression

A

CTX

B
NZF1/1Myt1l

DTe

LGE

Relative mRNA
Abundance

NZF2/Myt1
NZF3/Myt3/St18

MGE

VTe
OpV

POA

OpV
HT
E10.5

E12.5

E15.5

E18.5

P2

P7

P14

P21

VG

HT
HT

Adult

Time

E10.5

E9.5

C

E11.5

CTX
CTX

Mature neurons

APa
LGE

APa

MGE

LGE

CTX

IC
HC
TH

Str
MGE

Intermediate
progenitors

Pal

TH
HT

HT
POA

Neural progenitors

HT
E12.5

Myt1l wild-type cortex

Myt1l mutant cortex

E13.5

E14.5

NZF-1/MYT1L
NZF-2/MYT1
NZF-3/MYT3/ST18

Fig. 2 Mouse embryonic brain expression patterns of MYT family transcription factors. A Quantitative RT-PCR summarized as relative
mRNA expression of Myt1 (red), Myt1l (blue), and Myt3 (green) in the developing mouse from E10.5 to adult, adapted from [13]. B Color coded
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NEUROG1) as well as other developmentally expressed TFs such as
BRN2 and MYT1L. In vitro overexpression studies have shown that
the pioneer factor ASCL1 is sufﬁcient for induction of neuronal
traits, but overexpression in combination with other factors such
as BRN2, and especially, MYT1L is necessary for efﬁcient ﬁbroblasts
conversion to neurons as well as the maturation of the induced
neurons (iNs) [11, 26, 27]. Ultimately, many of these studies
suggest that MYT1L and other members of the MYT family
primarily function to preserve neuronal phenotypes as it has been
shown that MYT1L is mostly expressed during the postspeciﬁcation phase when cell populations have become postmitotic. Furthermore, none of the MYT family members were
observed to be expressed by in situ hybridization in germinal
zones containing mostly undifferentiated cells [13, 28], and very
little overlap (5%) was seen with SOX2 positive progenitors [15].
Interrogation of speciﬁc domains of MYT1L has further deﬁned its
role in neuronal conversion. For example, Mall et al. [11] showed
that, when fused to an activating element (VP64), the DNA binding
domains of MYT1L displayed a dominant-negative effect on
ASCL1-mediated neuronal conversion. In addition, just a 423amino-acid fragment (i.e., amino acids 200–623), which contains
the N-terminal domain and the middle two zinc ﬁngers, was
functionally indistinguishable from full-length MYT1L. Surprisingly,
this fragment does not contain the MYT1 domain.
In contrast to the overexpression studies discussed above,
knockdown of MYT1L via short hairpin (sh) RNAs resulted in a
reduction of neuronal maturation gene programs such as neurite
outgrowth, axonal development, synaptic transmission, and
extracellular matrix composition, which hints that MYT1L also
acts as an activator [29]. It has also been reported that MYT1L was
found to be deleted (~5%) and downregulated (>80%) in
glioblastomas, suggesting that gliomagenesis requires neutralization of terminal neural differentiation [30]. Furthermore, others
have shown that MYT1L and MYT1 expression can slow tumor
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growth in glioblastoma cell line models via repression of proproliferative genes [31]. However, impacts on glia in vivo are likely
not direct since MYT1L expression has not been consistently
observed in glia [15, 32].
Spatiotemporal expression of MYT family TFs is ﬁnely tuned
across development, speciﬁcally during neuronal maturation. Of
the MYT family, Myt1 and Myt3 are expressed the earliest at
embryonic (E) day 9.5 as suggested by in situ hybridization [13].
Quantitative RT-PCR results showed that Myt1 and Myt1l were
upregulated from E10.5 to E15.5 and then downregulated
postnatally (Fig. 2A) [13]. In addition, Myt1l mRNA levels increase
across neurogenesis in mice, and low levels are sustained in
adulthood, which mirrors human expression patterns [13]. In mice,
MYT1L protein levels were sustained from E14 (beginning) to
postnatal (P) day 1 and declined thereafter [15], but remained
detectable indeﬁnitely. The earliest time point of detectable Myt1l
expression occurs at E9.5 in the ventrolateral portion of the spinal
cord, again where newborn neurons are found. In addition, at
E12.5, BrdU staining to identify proliferating cells hardly overlapped with Myt1l expression, further supporting that Myt1lpositive cells were mostly post-mitotic [13]. Indeed, across the
multiple CNS regions examined (spinal cord, hindbrain, midbrain,
cortex, and retina), Myt1l mRNA was upregulated when neurons
began to differentiate (Fig. 2B) and overlapped with markers of
neurons. Overall, analysis of Myt1l expression pattern and time
course further supports the assumption that it is responsible for
neuronal maturation and preservation of cell fate.
Several in vivo studies have also shed light on MYT1L’s necessity
for neuronal maturation. In zebraﬁsh, knocking down human
MYT1L orthologs, myt1la and myt1lb, by antisense morpholinos
(MO) results in almost complete loss of oxytocin (OXT) and
arginine vasopressin (AVP) in the neuroendocrine pre-optic area of
the hypothalamus, suggesting MYT1L LoF might affect neuroendocrine system development [5]. This could either represent loss
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of these neurons, or loss of their maturation since neuropeptide
expression occurs relatively late in neuronal maturation [33]. In a
MYT1L Syndrome mouse model that displays MYT1L haploinsufﬁciency, precocious neuronal differentiation from progenitors to
immature neurons was observed upon MYT1L loss during early
brain development [15] (Fig. 2C). This suggests MYT1L LoF leads to
loss of proliferating cells during development and correspondingly a smaller brain in the adult, providing a mechanistic
explanation for the human patients’ microcephaly. In addition,
assessment in adults revealed MYT1L heterozygous mice show
impaired neuronal maturation in terms of transcriptional proﬁles,
neuronal morphology, and potentially neuronal electrical properties [15]. In summary, MYT1L may have multiple roles in
neurodevelopment, with strong evidence that at least one may
be promoting neuronal maturation.
MOLECULAR FUNCTIONS OF MYT1L
Functional domains within MYT1L
Structurally, MYT family TFs have several domains that may deﬁne
their functions and many initial studies of MYT family TFs focused
on the characterization of structural domains and DNA binding
[32, 34]. Amino acid sequence analysis of MYT1L isolated from rat
pituitary and cerebellum cell lines showed that the protein has six
zinc ﬁnger domains (Cys-Cys, His-Cys) that are organized into
clusters with one at the N-terminus, a pair upstream of the MYT1
domain, and three at the C-terminal domain [34]. Using AlphaFold
[23, 24] to model the structure of MYT1L, these six zinc ﬁnger
domains are predicted to come together to form a DNA binding
pocket (Fig. 1C, Supplemental Video 2). MYT1L LoF mutations
based on patient reports can be found throughout all domains of
the protein (Fig. 1D) with a notable cluster of mutations within the
central zinc ﬁnger domains (Fig. 1E). The N-terminus contains a
highly acidic region, and a Ser/Thr-rich region between the two
clusters of zinc ﬁngers [11].
The zinc ﬁngers are thought to be involved in DNA-binding. The
core sequence recognized by the MYT1L zinc ﬁngers, speciﬁcally
from the two zinc ﬁngers upstream of the MYT1 domain, is
GAAAGTT [34]. An additional GTT that resides 4 bp 5′ of the core
sequence element was observed in the DNA binding motif when
testing the construct with the three zinc ﬁngers at the C-terminal
end of the protein. Competitive binding assays showed that
AAGTT was the most crucial for binding [34], which is consistent
with the motif reported from ChIP-seq experiments [11]. Further,
two additional purines at the 5′ end (RRAAGTT) are preferred for
optimal binding. The N-terminus, which is the least conserved
domain among the MYT family of TFs, with its highly acidic region
that is enriched for Glu/Asp residues, has been implicated in
transcriptional activation [16, 34], a function that appears
dispensable for production of transdifferentiated neurons [11].
The N-terminus, MYT1 domain, and C-terminus of MYT1L also
contain structural components that are unique to the MYT family.
The MYT1 and C-terminal domains are highly conserved across the
MYT family, and the MYT1 domain contains a Ser/Thr-rich region
in both MYT1 and MYT1L [11, 34]. Several studies used these
speciﬁc fragments of MYT1 and MYT1L to characterize the
transcriptional effects of each protein, which is discussed more
in the ﬁnal section of the review.
KEY QUESTIONS AND FUTURE DIRECTIONS
What are the targets of MYT1L?
The emerging role of MYT1L in NDDs highlights the importance of
a more complete understanding of MYT1L within transcriptional
networks, and the identiﬁcation of its targets is essential to
systematically study the downstream consequences of MYT1L
haploinsufﬁciency. Thus far, identiﬁcation of MYT1L-regulated
genes has been addressed via in vitro overexpression or

knockdown studies followed by analysis of changes in gene
expression. For example, ﬁbroblast gene signatures were found to
be downregulated by RNA-seq upon induction of iNs [11]. In
particular, MYT1L repressed Notch signaling and Hes1 to promote
neurogenesis, and acute shRNA knockdown of MYT1L phenocopied Notch gain-of-function.
While studies of gene expression are informative, they do not
distinguish between direct and indirect regulation. Direct targets
have been identiﬁed by ChIP-seq primarily in ﬁbroblasts overexpressing MYT1L and with limited samples from endogenous
MYT1L in the developing mouse brain [11]. Within a subset of
ChIP-seq peaks, the previously described AAGTT motif was
enriched within downregulated genes in ﬁbroblasts, consistent
with the hypothesis of MYT1L’s role as a transcriptional repressor.
However, the direct targets in vivo tended to show a loss of
chromatin accessibility and expression in MYT1L mutants,
suggesting the loss of an activator [15]. It may also be that
MYT1L binding has distinct functions at different sites or occurs in
a context-dependent manner. Regardless, little is known about
MYT1L binding at other time points (embryonic vs. adult), or how
binding and activity changes in haploinsufﬁciency. To detect
subtle effects and to understand the observed changes in
chromatin and gene expression in MYT1L models, an atlas of
MYT1L binding sites is needed (e.g., a high-quality time course
ChIP-seq or CUT&RUN experiment). In addition, binding peaks can
be quantiﬁed to determine changes in TF binding in a
concentration-dependent manner, which will be critical in
identifying differentially bound genomic regions and gene
expression in MYT1L haploinsufﬁcient mice.
How the impact of MYT1L loss changes across cell types is also
unclear. There have been signiﬁcant developments in multiomic
assays for directly linking chromatin accessibility to the transcriptome within the same single cells. Coupled with the MYT1L
syndrome mouse model, this would be a powerful assay to
address the questions of how MYT1L loss affects chromatin state
and whether this loss disproportionately affects a speciﬁc neural
cell subtype. One inherent limitation to most “omic” methodologies is that they only capture a snapshot of the “-ome” at the
time of sample collection. An emerging method, Calling Cards,
seeks to preserve historical cell states by recording TF-DNA
interactions over time [35, 36]. This cumulative history of the
location of TF binding across time can generate a unique dataset
to link TF binding, transcription, cell fate decisions, and developmental trajectories in single cells, which might be of interest to
apply here. Overall, a more complete catalog of MYT1L targets in
speciﬁc neural subtypes will be key to understanding the
mechanisms underlying the observed phenotypes following LoF
mutation.
What are the modes of MYT1L TF binding?
Our ability to associate TF binding with gene expression is still
imperfect, and it is unclear if MYT1L binds in a direct mode to
DNA, or if it requires cofactors (indirect mode) for some DNA
interactions. ChIP-seq and motif discovery algorithms are efﬁcient
at identifying direct TF binding sites (usually within ~50 bp).
However, these methods also capture indirect TF-DNA interactions through other TFs that bind cooperatively. This becomes
apparent when sequences bound in vivo differ from those that
are found in vitro [37]. Also, as patients are MYT1L haploinsufﬁcient, one could speculate that MYT1L binding targets are
dependent on the concentration of MYT1L. In addition to motif
sequence speciﬁcity and intra- and intermolecular TF interactions,
adjacent ﬂanking sequences are also key determinants of TF
binding and regulation. Thus, additional studies and methodologies that can differentiate between direct and indirect TF
binding and link these dynamics to cis regulatory elements will
be important to understanding the consequences of altered
MYT1L levels on gene expression.
Translational Psychiatry (2022)12:292
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Based on ChIP-seq data of reprogrammed iNs, MYT1L binding
sites are enriched in transcription start sites, whose corresponding
genes were often repressed during ﬁbroblast-to-neuron transdifferentiations [11]. However, such overexpression of MYT1L could
lead to interactions not found under physiological conditions.
Moreover, the accessibility of putative MYT1L targets may be
inﬂuenced by the indirect effects of reprogramming ﬁbroblasts
into neurons. MYT1L ChIP-seq provides a readout of direct targets
of MYT1L, but a complete understanding of its DNA binding motif
is often difﬁcult or impossible to glean from this data alone.
Indeed, most peaks do not show the known MYT1L motif,
suggesting that much of MYT1L binding is indirect. Thus, MYT1L
ChIP-seq is important in determining TF binding in a speciﬁc
biological context, but complementary methods are still needed
to understand binding preferences. SELEX (also known as SAAB or
CASTing), is a cell-free assay that has been adapted to screen for
sequences that bind a TF of interest [38, 39]. Both high and
intermediate afﬁnity sequences can be captured and used to
characterize binding afﬁnities. This method enabled the de novo
motif discovery and conﬁrmation of MYT1L binding sites [11], but
it would be difﬁcult to assay ﬂanking sequences and intermolecular interactions that can affect MYT1L binding in vivo. Several
open questions remain. Does MYT1L require cooperative binding,
or can it function independently? Although MYT1L is not known to
have pioneering abilities, can its binding prevent chromatin
remodeling/nucleosome repositioning? Can cofactors alter the
motif sequence speciﬁcity of MYT1L? A better understanding of
MYT1L TF biology and the determinants contributing to its
binding will be critical in understanding its functions and the
consequences of its dysfunctions.
Is MYT1L an activator or a repressor?
Once MYT1L binds to DNA, whether it functions as a transcriptional activator, repressor, or both, is still not clearly understood. In
vitro transdifferentiation studies have represented MYT1L as a
repressor of non-neuronal gene programs [11, 14], while other
in vivo studies have found evidence that MYT1L activates
neuronal genes [15, 29]. Early in vitro studies show that MYT1L
was able to activate a hRARβ promoter-luciferase reporter as well
as a Pit-1 enhancer/promoter luciferase reporter in CV-1 and HeLa
cells [34]. Furthermore, MYT1 and MYT1L were directly compared
using an in vitro reporter with a synthetic promoter carrying seven
copies of the AAAGTTT motif separated by nine nucleotides [16].
In this assay, overexpression of full-length MYT1 repressed
transcription while overexpression of full-length MYT1L activated
transcription of the reporter in HeLa, A549, and U87 cells, which all
have relatively low or no endogenous MYT1 and/or MYT1L
expression. In cultured neuronal cells, shRNA-mediated knockdown of MYT1L resulted in reduced expression of neuronal
transcripts associated with neurite outgrowth, axonal development, and synaptic transmission [29]. This is consistent with recent
data from a germline MYT1L heterozygous mouse model showing
increased expression of “early fetal” genes in prefrontal cortex of
adult mice, resulting in an immature transcriptional signature
compared to wild-type (WT) mice [15].
MYT1L also contains a repressive MYT1 domain. Compared to
the N-terminal activation domain, the MYT1 domain appears to be
highest conserved region second to the middle and C-terminal
zinc ﬁngers, containing the Ser/Thr-rich region in MYT1 and
MYT1L [11, 34] (Fig. 1A), and appears repressive in most studies so
far. Mechanistically, through a yeast-two-hybrid screen, the central
domain of MYT1 was shown to interact with the corepressor
SIN3B. Since this region is conserved across the MYT family, it was
also shown that MYT1L interacted with SIN3B using a Gal4 assay
[12], and other studies have supported the conclusion that the
central, MYT1 domain can interact with the corepressor SIN3B [11].
Speciﬁcally, the interaction between MYT1 and MYT1L with SIN3B
can result in transcriptional repression via histone deacetylase
Translational Psychiatry (2022)12:292

(HDAC) interaction with SIN3B [12]. When directed to promoter
regions by MYT1 and MYT1L, the SIN3B-HDAC complex can
remove activating chromatin modiﬁcations, resulting in less
accessibility and ultimately, repression [12].
The seemingly divergent functions of the activating N-terminal
domain and repressive MYT1 domain make it challenging to
classify MYT1L as a transcriptional activator or repressor.
Altogether, these focused studies on the molecular domains of
MYT1L suggest that the role of MYT1L is context dependent and
may largely function as an activator in vivo. Follow-up studies are
needed to determine if the role of MYT1L remains the same in
adulthood after neurodevelopment has been completed.
To analyze the molecular and cellular role of MYT1L during
neurodevelopment, a detailed time-course analysis of chromatin
accessibility and TF binding is required. Single-cell/nuclei
technologies can be leveraged to identify the cis regulatory
landscapes and trajectories of the different cell types that make
up the brain [40]. This general approach can be used with the
MYT1L Syndrome mouse model to map altered gene regulatory
programs and resulting impact on cellular proportions upon loss
of MYT1L. Traditional methods to assay the TF activation or
repression utilize ﬂuorescence or luciferase-based reporter
constructs for a quantitative readout of downstream activities.
While these are highly sensitive and reproducible, they are not
suitable for high-throughput screening of hundreds of putative
regulatory elements. Massively parallel reporter assays (MPRAs)
are an approach that can be used to test the cis regulatory
function of thousands of DNA sequences in one experiment and
can be deployed in vivo in a cell-type-speciﬁc manner [41]. The
main limitation is that these ~150 bp synthetic libraries are taken
out of their original context, so additional validation experiments
are necessary. Looking at chromatin accessibility and MYT1L TF
binding together with functional assays could provide insight into
the context-dependent role of MYT1L as an activator and/or
repressor.
How does MYT1L impact progenitor proliferation?
MYT1L also seems to have mixed inﬂuences on cell proliferation in
different systems. In vitro ﬁbroblast studies have shown MYT1L
overexpression suppresses cell cycle programs [11], while MYT1L
KO mice displayed decreased cell proliferation in the developing
cortex [15]. If MYT1L is expressed in postmitotic neurons and at
very low levels in ﬁbroblasts and progenitors, how does MYT1L
regulate cell proliferation in each of these cell types? During
ﬁbroblast transdifferentiation to neurons, MYT1L’s repressive role
on cell cycle programs might be the by-product of the
transdifferentiation process since related pathways, like Notch
signaling, are suppressed during neuronal differentiation [42]. The
nature of the MYT1L-ASCL1-BRN2 ﬁbroblast overexpression
system makes it hard to delineate normal functions of MYT1L
itself. Because of this, MYT1L KO mice might help better
understand how MYT1L regulates cell cycle under physiological
conditions. One hypothesis is that the effect is cell autonomous:
that MYT1L is expressed in a small proportion of intermediate
progenitors (IP; which has been observed in [15]), and this
prevents early differentiation of IPs to mature neurons, thus
maintaining progenitor pools. Thus, loss of MYT1L leads to
precocious IP differentiation and depletion of progenitors in the
developing mouse cortex (Fig. 2C). An alternative, non-cell
autonomous hypothesis is that MYT1L loss from differentiating
neurons (which have robust MYT1L expression normally), might
decrease a lateral inhibition signal that normally prevents the
differentiation of nearby neural precursors—potentially via
decreased Delta like ligand (DII), known to play a role in lateral
inhibition [43, 44]. Both hypotheses could explain the observed
down-regulation of the cell cycle programs in bulk RNA-seq
experiments. To further dissect how MYT1L impacts cell proliferation either cell autonomously or non-cell autonomously, mosaic
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Fig. 3 Speculative “ready-set-go” model of MYT TFs during
neuronal differentiation. A “Ready” phase: initial expression of
MYT1 during early neurodevelopment represses non-neuronal and
neuronal maturation gene expression programs. B “Set” phase:
MYT1 expression fades and is replaced by MYT1L and is still net
repressive to prevent maturation gene expression. This ensures
maintenance of the progenitor pool. C “Go” phase: MYT1L, due to
possible interactions with cofactors, postransciptional modiﬁcations,
or increased expression levels activates the expression of neuronal
maturation genes. Figure created with BioRender.com.

deletions and/or single-cell sequencing on MYT1L mutant mouse
cortex could be applied.
How might MYT family members interact to promote neuronal
differentiation?
How do the known expression patterns and their molecular
functions as activators and/or repressors for this family of proteins
inform our knowledge of their role in neurodevelopment? One
model that might ﬁt both the expression pattern, binding pattern,
and what is known so far about the molecular function of the MYT
family would be a “ready-set-go model” (Fig. 3). Speculatively, as
progenitors get “ready” to differentiate into neurons, MYT1 may
be expressed ﬁrst, where it binds to and represses promoters of
non-neuronal genes to silence them, and of neuronal genes to
prevent them from expressing too early (i.e., so as not to form
synapses during early phases of migration). As differentiation
progresses (“set”), MYT1 levels fade and MYT1L begins to be
expressed, so that it gradually replaces MYT1 at these same sites
but remains initially repressive. However, with time, MYT1L
binding at neuronal promoters transitions from repressive to
activating, thus promoting (“go”) maturation in gene expression.
This last transition could be mediated by the arrival of newly
expressed proneuronal cofactors (e.g., NEUROD1) that could
synergize with MYT1L’s N-terminal activating domain, or posttranslational modiﬁcation to block interaction with SIN3B, or even
changes in the amount of MYT1L at a given locus over time
allowing for saturation of adjacent lower afﬁnity sites and
alteration of regulatory activity. The co-factor model would allow
it to become an activator at different genomic sites at different
times, depending on adjacent motifs for interacting partners.
While speculative, the model could explain the data so far, and is
testable in future studies.
What cell types are driving the observed clinical phenotypes?
In vitro transdifferentiation studies, in vivo knockdown experiments, and analysis of the cortex from MYT1L heterozygous mice
all show that MYT1L is important for neuronal development and

maturation. In general, loss or knockdown of MYT1L leads to an
increase of an immature neuron transcriptional proﬁle and
decrease of a mature neuron transcriptional proﬁle in adults.
However, given the pan-neuronal expression of MYT1L, one can
wonder if certain subtypes of neurons could be more sensitive to
the loss of MYT1L, with distinct cell types leading to each of the
diverse panel of clinical phenotypes such as obesity, white-matter
thinning, hyperactivity, and social deﬁcits. Likewise, initial results
suggest that neural progenitors may be precociously differentiated, leading to a reduced pool of progenitors. However, further
studies will need to be done to determine if this leads to altered
ﬁnal proportions of cell types in the cortex and other implicated
brain regions such as the hypothalamus. In addition, the possibility
of a non-cell autonomous role of MYT1L on glia, and the
importance of that to patient phenotypes, remains to be explored.
While the observed phenotypes during embryonic development
are likely cell autonomous due to lack of mature glia at this
developmental stage, further studies (e.g., single-cell sequencing)
are needed to deconvolve non-cell autonomous effects.
Another possibility is that the clinical phenotypes are driven
more by anomalies in the connections between cells (i.e., circuit
deﬁcits) rather than cell autonomous effects—a possibility that
has so far been unexamined. Electrophysiological studies in
haploinsufﬁcient models have been limited to patch clamp of
individual visual cortex neurons, which identiﬁed excitatory/
inhibitory (E/I) imbalance in pyramidal neurons [15]. Thus, it
would be of interest to examine circuit properties as well as
functional connectivity in this system to determine if these cellular
deﬁcits result in circuit miswiring or dysfunction. Likewise, there is
an interesting hypothesis from the Greenberg lab proposing the
fundamental deﬁcit in NDDs, especially for those mediated by
mutations in TFs like MYT1L, is a disruption in the stereotyped
pattern of activity-dependent gene expression that is required for
the changes in synaptic strength underlying learning and memory
[45]. An inability for gene expression to support functional
changes in circuits in response to experience could also lead to
anomalous behaviors in MYT1L haploinsufﬁcient mice. Thus, there
is an opportunity for better measures of circuit function and its
relation to gene expression in these mutants. Such knowledge of
the susceptible cell types and circuits will be key to guiding
targeted strategies to rescue MYT1L function in speciﬁc cell
populations for potential translational beneﬁt.
CONCLUDING REMARKS AND PERSPECTIVES
Better understanding of MYT1L’s mechanism, function, and
protein structure will be key for accurately interpreting how a
LoF mutation can contribute to the diverse observed clinical
phenotypes. As the expression of MYT1L peaks perinatally with
continued low expression throughout adulthood, temporal
analysis of changes arising from acute and chronic MYT1L
dysfunction will be important to determine an effective therapeutic window. Finally, as MYT1L is a neuron-speciﬁc panneuronal TF, studying the molecular and cellular disruptions at
both the single cell and circuit levels can be fruitful to identify
susceptible cell populations and perturbed networks. This
approach can enable focused investigations into relevant cell
populations and pathogenic mechanisms, potentially resulting in
the future development of targeted therapeutic strategies.
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